Trial Profile
A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Two Different Doses of a Topical Minocycline Foam Compared to Vehicle in the Treatment of Papulopustular Rosacea - Study FX2015-10.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Minocycline (Primary)
- Indications Rosacea
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMIRA
- Sponsors Foamix; VYNE Therapeutics
- 30 Jul 2019 According to an Foamix Pharmaceuticals media, the company has received financing from Perceptive Advisors and OrbiMed which will be used to fund the company's filing of a New Drug Application(NDA) with the FDA for FMX103 for the treatment of papulopustular rosacea. Also the company is in the final stages of preparation for the NDA submission for FMX103.
- 02 Feb 2018 Results (n=232) assessing the efficacy and safety of two doses of topical minocycline foam with that of vehicle foam for the treatment of papulopustular rosacea, were published in the American Journal of Clinical Dermatology.
- 12 Jun 2017 Results published in a Foamix media release.